Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
复制标题
DOI：
10.1002/ijc.29163
复制
发表时间：
2015-04-01
影响因子：
6.4
通讯作者：
Kodera, Yasuhiro
中科院分区：
文献类型：
--
作者：
Tan, Gewen;Kasuya, Hideki;Kodera, Yasuhiro
乳腺癌是女性最常见和最害怕的癌症之一。尽管涉及化疗和激素药物的多模式治疗有所改进，但晚期或复发性乳腺癌患者的预后仍然很差。迫切需要具有更具体和有效策略的多模式治疗。溶瘤单纯疱疹病毒（HSV）因其广泛的宿主范围和肿瘤选择性病毒分布而有可能成为一种新的有效治疗选择。贝伐珠单抗是一种针对 VEGFA 的单克隆抗体，可抑制血管生成，从而抑制肿瘤生长。我们增强溶瘤HSV抗肿瘤作用的方法是将溶瘤HSV HF10与贝伐单抗联合治疗乳腺癌。我们的结果表明，贝伐珠单抗增强了病毒分布以及肿瘤缺氧，并扩大了凋亡细胞的数量，因此诱导了协同抗肿瘤作用。 HF10 有望成为与贝伐单抗联合用于抗癌治疗的有前景的药物。
Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.